Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
New patients can pay $199/month for the first 2 months (0.25 mg or 0.5 mg doses through March 31, 2026)
Retatrutide is a triple-agonist research peptide studied for its interaction with GIP, GLP-1, and glucagon receptors
The National Sanitation Foundation (NSF) grants its seal of approval when it determines that a product, its manufacturing process, and the manufacturing facility comply with its internal requirements
This is especially appealing to individuals dealing with chronic joint discomfort, lingering injuries, or slow recovery
Providers may recommend Rybelsus for patients unwilling to try injectables, while reserving Ozempic or Wegovy (injectable semaglutide for obesity) for those needing higher efficacy
US$ 28.05
US$ 29.67
US$ 27.87
US$ 28.28
